AMA submission to the Therapeutic Goods Administration – Proposed amendments to the Poisons Standard – mometasone, zolmitriptan, sumatriptan, caffeine
The AMA opposes the proposal to downschedule mometasone for dermal use on the grounds of patient safety. The AMA supports increased access to zolmitriptan and sumatriptan however there needs to be increased pharmacist education around accurate migraine diagnosis and limits on the number of times a patient can purchase this medication until it is recommended that the patient should consult a medical practitioner. The AMA has no objections to the proposed new Schedule 4 and 6 entries for caffeine.
Published: 17 Oct 2019